SLC6A3 and Parkinson disease: As further examples of these human-NHP neuroanatomical and neurophysiological similarities, the primate progressive model of Parkinson’s disease has also identified reduced density of dopamine transporter-immunoreactive axons in the MD at the earliest stages of treatment that further decrease when the monkeys become parkinsonian68.